
During Q2, sclerosis treatment Kesimpta brought in USD 66m to Novartis, the company financial report released on Wednesday states.
Kesimpta is far from the biggest treatment in Novartis' portfolio - Cosentyx, a psoriasis treatment, took that title in Q2 - but is nonetheless a growing asset for the company.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app